ArticleEJNMMI research2025
Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myeloma.
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
backgroundRadiological imaging plays an indispensable role in both preclinical and clinical studies of multiple myeloma (MM). However, manual quantification in longitudinal small animal PET/CT is limited by annotator bias, signal artifacts from urinary/fecal excretion, and voxel misalignment due to non-rigid registration. To address these challenges and improve characterization of tumor biology, we developed a semi-automated PET/CT quantification pipeline targeting defined regions of interest (ROIs) within the bone marrow-rich mouse skeleton, achieving sub-organ spatial resolution, including in anatomically complex sites such as the pelvis. We applied this MM-specific preclinical pipeline to analyze tumor distribution in a longitudinal molecular PET study using an immunocompetent mouse model of skeletally disseminated MM. An Attention U-Net was trained to segment the thoracolumbar spine, pelvis and pelvic joints, sacrum, and femurs from 2D CT slices. A custom algorithm masked spillover signal from physiological excretion, and a PCA-based projection was used to map tumor distribution along the skeletal axis. Quantification metrics included mean and maximum standardized uptake values (SUV
resultsTumor burden localized preferentially to skeletal regions near joints. Using precise CT-based alignment (DICE = 0.966 ± 0.005), we detected early disease progression and aggressive phenotypes. A marked increase in tumor uptake was observed by day 18 post-implantation, with significant SUV
conclusionsThis pipeline enables reproducible, anatomically precise quantification of region-specific trends in MM progression, including joint-specific lesion tropism and sex-based differences, from longitudinal PET/CT scans. By mitigating common challenges such as excretion artifacts and inconsistent mouse positioning, our approach overcomes limitations of manual analysis and enhances evaluation of tumor biology and treatment response in preclinical models of bone-involved cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.